Johnson & Johnson (NYSE: JNJ) recently received a number of ratings updates from brokerages and research firms:

  • 9/30/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $148.00 price target on the stock.
  • 9/27/2017 – Johnson & Johnson was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition.  However, J&J is optimistic that sales growth will accelerate in 2H17. We believe that new drugs like Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH – which should contribute to sales growth. J&J’s shares have outperformed the industry this year so far. However, headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment is also a concern. Meanwhile, HCV sales continue to decline in the face of intense competition. “
  • 9/25/2017 – Johnson & Johnson is now covered by analysts at Citigroup Inc.. They set a “neutral” rating and a $140.00 price target on the stock.
  • 9/20/2017 – Johnson & Johnson was downgraded by analysts at Goldman Sachs Group, Inc. (The) from a “neutral” rating to a “sell” rating. They now have a $130.00 price target on the stock, up previously from $125.00.
  • 9/18/2017 – Johnson & Johnson was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $130.49 price target on the stock.
  • 9/1/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $145.00 price target on the stock.
  • 8/31/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $148.00 price target on the stock.
  • 8/24/2017 – Johnson & Johnson was given a new $147.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 8/24/2017 – Johnson & Johnson had its “underweight” rating reaffirmed by analysts at UBS AG.
  • 8/16/2017 – Johnson & Johnson had its price target raised by analysts at J P Morgan Chase & Co from $140.00 to $148.00. They now have an “overweight” rating on the stock.
  • 8/15/2017 – Johnson & Johnson was given a new $145.00 price target on by analysts at Jefferies Group LLC. They now have a “hold” rating on the stock.
  • 8/4/2017 – Johnson & Johnson had its “buy” rating reaffirmed by analysts at Credit Suisse Group.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.67% during trading on Tuesday, reaching $132.10. The company had a trading volume of 3,900,754 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The stock has a market capitalization of $354.56 billion, a price-to-earnings ratio of 22.35 and a beta of 0.78. The company’s 50 day moving average is $132.31 and its 200-day moving average is $129.75.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same quarter in the prior year, the firm earned $1.74 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities research analysts anticipate that Johnson & Johnson will post $7.18 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 56.76%.

In other news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the sale, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at $30,993,466.96. The disclosure for this sale can be found here. Company insiders own 0.19% of the company’s stock.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.